Information Provided By:
Fly News Breaks for November 25, 2019
Nov 25, 2019 | 06:58 EDT
BTIG analyst Tim Chiang initiated coverage of Flexion with a Buy rating and $27 price target. The analyst says that based on his assessment of the osteoarthritis knee pain market, the sales growth of its Zilretta could continue to accelerate into 2020 with up to $500M in sales seen by 2025. Chiang adds that Zilretta is "just scratching the surface" in that some 30M Americans are expected to suffer from knee pain, and sales have accelerated since Flexion received Medicare reimbursement for the treatment.
News For FLXN From the Last 2 Days
There are no results for your query FLXN